Bringing Creativity to World Markets

Dexcel Pharma is synonymous with innovation. We excel at identifying opportunities and patient needs and then developing and commercializing real value-add products.

Where others see obstacles, we see opportunities.

Our company growth is built on a solid record of accomplishment in developing novel drug formulations, overcoming formidable manufacturing challenges and tacking regulatory barriers to bring valuable pioneering products to market. This proactive ability to recognize opportunities and execute complex development and manufacturing in such a fast-paced competitive market has allowed us to create new gold standards in several niche areas, increase access to better and affordable dose formulations for patients and enjoy consistent success and growth.

 

New Molecule Entity
Novel Drug Delivery
Drug Repositioning
New Galenic Forms
Complex Generics
Generics
PerioChip®
Undisclosed
Novel OTC formulation
Omeprazole DR Tablets
Complex Injectable
(Co-development)
ViePax® XR
(Venlafaxine XR tablets)
Atorvastatin
PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

Novel OTC formulation

Novel Formulation of a well-known US OTC Brand

Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC

Complex Injectable
(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma

ViePax® XR
(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules